• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Lecia V. Sequist, MD, MPH

Publications

  • Camidge DR, Pao W, Sequist LV.Acquired resistance to TKIs in solid tumours: learning from lung cancer.Nat Rev Clin Oncol. 2014 Jul 1.
    24981256
  • Miyamoto DT, Sequist LV, Lee RJ.Circulating tumour cells-monitoring treatment response in prostate cancer.Nat Rev Clin Oncol. 2014 May 13.
    24821215
  • Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA.Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.JAMA. 2014 May 21;311(19):1998-2006.
    24846037
  • Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA.Isolation and Molecular Characterization of Circulating Melanoma Cells.Cell Rep. 2014 Apr 16.
    24746818
  • Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.Sci Transl Med. 2013 Dec 18;5(216):216ra177.
    24353160
  • Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV.Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.Oncologist. 2013;18(11):1214-20.
    24072220
  • Pfäffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, Settleman J, Benes CH, Sequist LV, Zou L, Willers H.EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.Cancer Res. 2013 Oct 15;73(20):6254-63.
    23966292
  • Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV.Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.J Clin Oncol. 2013 Sep 20;31(27):3342-50.
    23816967
  • Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M.Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol. 2013 Sep 20;31(27):3327-34.
    23816960
  • Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M.The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.Ann Thorac Surg. 2013 Sep;96(3):962-8.
    23932319
  • Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI.A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Clin Cancer Res. 2013 Jun 1;19(11):3068-77.
    23553849
  • Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W.Characteristics of Lung Cancers Harboring NRAS Mutations.Clin Cancer Res. 2013 Apr 18.
    23515407
  • Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M.Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.Sci Transl Med. 2013 Apr 3;5(179):179ra47.
    23552373
  • Birkelbach M, Ferraiolo N, Gheorghiu L, Pfäffle HN, Daly B, Ebright MI, Spencer C, O'Hara C, Whetstine JR, Benes CH, Sequist LV, Zou L, Dahm-Daphi J, Kachnic LA, Willers H.Detection of impaired homologous recombination repair in NSCLC cells and tissues.J Thorac Oncol. 2013 Mar;8(3):279-86.
    23399959
  • Pirl WF, Traeger L, Greer JA, Jackson V, Lennes IT, Gallagher E, Sequist L, Temel JS.Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer.Palliative & Supportive Care. 2013 Feb 11:1-7.
    23399428
  • Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S.Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.Science. 2013 Feb 1;339(6119):580-4.
    23372014
  • Sequist LV.ROS1-targeted therapy in non-small cell lung cancer.Clin Adv Hematol Oncol. 2012 Dec;10(12):827-8.
    23271356
  • Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ.FGFR1 amplification in squamous cell carcinoma of the lung.J Thorac Oncol. 2012 Dec;7(12):1775-80.
    23154548
  • Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA.Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.Cancer Discovery. 2012 Nov;2(11):995-1003.
    23093251
  • Moran T, Sequist LV.Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.J Clin Oncol. 2012 Sep 20;30(27):3330-6.
    22753908
  • Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV.A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.J Thorac Oncol. 2012 Oct;7(10):1602-8.
    22878749
  • Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W.Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33.
    22773810
  • Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA.RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis.Nature. 2012 Jul 26;487(7408):510-3.
    22763454
  • Heist RS, Sequist LV, Engelman JA.Genetic changes in squamous cell lung cancer: a review.J Thorac Oncol. 2012 May;7(5):924-33. Review.
    22722794
  • Neal JW, Sequist LV.Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.J Clin Oncol. 2012 Jun 20;30(18):2280-2.
    22508823
  • Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA.Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors.Sci Transl Med. 2011 Mar 23;3(75):75ra26.
    21430269
  • Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, Sequist LV.Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.Oncologist. 2011;16(3):319-26.
    21339258
  • Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R.Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer.J Clin Oncol. 2010 Nov 20;28(33):4953-60.
    20940188
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
    20979469
  • Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M.Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18392-7.
    20930119
  • Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV.Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.J Thorac Oncol. 2010 Nov;5(11):1855-8.
    20975380
  • Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV.EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.Neuro Oncology. 2010 Nov;12(11):1193-9.
    20627894
  • Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ.Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.J Thorac Oncol. 2010 Oct;5(10):1637-43.
    20808253
  • Neal JW, Sequist LV.Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.Curr Treat Options Oncol. 2010 Jun;11(1-2):36-44.
    20676809
  • Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC.Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.J Clin Oncol. 2010 Jun 20;28(18):3076-83.
    20479403
  • Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.EMBO Mol Med. 2010 May;2(5):146-58.
    20432502
  • Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S.Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.Sci Transl Med. 2010 Mar 31;2(25):25ra23.
    20424012
  • Neal JW, Sequist LV.First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.Clin Adv Hematol Oncol. 2010 Feb;8(2):119-26. Review.
    20386533
  • Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.Cancer Cell. 2010 Jan 19;17(1):77-88.
    20129249
  • Neal JW, Sequist LV.Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.Nat Rev Clin Oncol. 2010 Feb;7(2):71-2.
    20118973
  • Sequist LV.Protein degradation/chaperone system and histone deacetylase pathway.J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1077-8.
    19861924
  • Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ.Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.J Thorac Oncol. 2009 Nov;4(11):1389-96.
    19701107
  • Sequist LV, Fidias P, Heist RS, Ostler P, Muzikansky A, Lynch TJ.Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.J Thorac Oncol. 2009 Sep;4(9):1170-3.
    19704338
  • Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.Clin Cancer Res. 2009 Aug 15;15(16):5267-73.
    19671843
  • Pirl WF, Solis J, Greer J, Sequist L, Temel JS, Lynch TJ.Epidermal growth factor receptor tyrosine kinase inhibitors and depression.J Clin Oncol. 2009 Aug 10;27(23):e49-50; author reply e51.
    19597022
  • Sequist LV,Engelman JA,Lynch TJ.Toward noninvasive genomic screening of lung cancer patients.J Clin Oncol. 2009 Jun 1;27(16):2589-91.
    19414671
  • Sequist LV,Nagrath S,Toner M,Haber DA,Lynch TJ.The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.J Thorac Oncol. 2009 Mar;4(3):281-3.
    19247082
  • Chin TM,Quinlan MP,Singh A,Sequist LV,Lynch TJ,Haber DA,Sharma SV,Settleman J.Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.Clin Cancer Res. 2008 Nov 1;14(21):6867-76.
    18980981
  • Costa DB,Nguyen KS,Cho BC,Sequist LV,Jackman DM,Riely GJ,Yeap BY,Halmos B,Kim JH,Janne PA,Huberman MS,Pao W,Tenen DG,Kobayashi S.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Clin Cancer Res. 2008 Nov 1;14(21):7060-7.
    18981003
  • Heist RS,Fidias P,Huberman M,Ardman B,Sequist LV,Temel JS,Lynch TJ.A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.J Thorac Oncol. 2008 Oct;3(10):1153-8.
    18827612
  • Sequist LV,Settleman JE,Ackman JB,Iafrate AJ.Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.N Engl J Med. 2008 Jul 24;359(4):405-14.
    18650517
  • Maheswaran S,Sequist LV,Nagrath S,Ulkus L,Brannigan B,Collura CV,Inserra E,Diederichs S,Iafrate AJ,Bell DW,Digumarthy S,Muzikansky A,Irimia D,Settleman J,Tompkins RG,Lynch TJ,Toner M,Haber DA.Detection of mutations in EGFR in circulating lung-cancer cells.N Engl J Med. 2008 Jul 24;359(4):366-77.
    18596266
  • Sequist LV.First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S143-5. Review.
    18520299
  • Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12.
    18520291
  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations.J Clin Oncol. 2008 May 20;26(15):2442-9.
    18458038
  • Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G.A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):204-11.
    18199725
  • Sequist LV, Lynch TJ.EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story.Annu Rev Med. 2008;59:429-42. Review.
    17716025
  • Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M.Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature. 2007 Dec 20;450(7173):1235-9.
    18097410
  • Oxnard GR, Fidias P, Muzikansky A, Sequist LV.Non-small cell lung cancer in octogenarians: treatment practices and preferences.J Thorac Oncol. 2007 Nov;2(11):1029-35.
    17975495
  • Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS.Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4583-8.
    17671145
  • Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ.Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.J Mol Diagn. 2007 Jul;9(3):320-6.
    17591931
  • Sequist LV, Dziadziuszko R.Update on epidermal growth factor receptor inhibitor development in lung cancer.J Thorac Oncol. 2006 Sep;1(7):740-3.
    17409951
  • Sequist LV.Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Oncologist. 2007 Mar;12(3):325-30. Review.
    17405897
  • Sequist LV, Bell DW, Lynch TJ, Haber DA.Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.J Clin Oncol. 2007 Feb 10;25(5):587-95. Review.
    17290067
  • Sequist LV, Joshi VA, Jnne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Oncologist. 2007 Jan;12(1):90-8.
    17285735
  • Sequist LV, Joshi VA, Jnne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.Epidermal growth factor receptor mutation testing in the care of lung cancer patients.Clin Cancer Res. 2006 Jul 15;12(14):4403s-8s. Review.
    16857818
  • Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jnne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.Clin Cancer Res. 2006 Jul 15;12(14):4365s-71s.
    16857812
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jnne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res. 2006 Jul 1;12(13):3908-14.
    16818686
  • Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM.Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.Blood. 2005 Dec 15;106(13):4389-96.
    16131571
  • Sequist LV, Haber DA, Lynch TJ.Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.Clin Cancer Res. 2005 Aug 15;11(16):5668-70.
    16115901
  • Sequist LV, Fidias P.Treatment of advanced non-small cell lung cancer in the elderly.Semin Respir Crit Care Med. 2005 Jun;26(3):289-97.
    16052430
  • Sequist LV, Lynch TJ.Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!.J Clin Oncol. 2003 Sep 1;21(17):3186-8.
    12874267